Fennec Pharmaceuticals has filed a patent for an anhydrous sodium thiosulfate compound and its synthesis method, along with a pharmaceutical composition for treating ototoxicity in pediatric patients receiving platinum-based chemotherapeutics. The composition includes sodium thiosulfate at a concentration between 0.3 M and 0.6 M, along with a buffer selected from carbonate, maleate, citrate, isocitrate, succinate, aspartate, and glutamate at a concentration between 0.01 M and 0.05 M. GlobalData’s report on Fennec Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Fennec Pharmaceuticals, nanoparticle drug conjugates was a key innovation area identified from patents. Fennec Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for treating ototoxicity in pediatric patients
A recently filed patent (Publication Number: US20230201351A1) describes a pharmaceutical composition that includes sodium thiosulfate and a buffer. The composition is intended for medical use and is formulated with specific concentrations of sodium thiosulfate and the buffer.
The patent claims that the pharmaceutical composition comprises sodium thiosulfate at a concentration between about 0.3 M and about 0.6 M. Additionally, the composition includes a buffer at a concentration between about 0.01 M and about 0.05 M. The buffer can be selected from a range of options, including carbonate, maleate, citrate, isocitrate, succinate, aspartate, and glutamate.
The patent also mentions that the sodium thiosulfate used in the composition can be aqueous anhydrous sodium thiosulfate. Furthermore, the composition may include a base, with sodium hydroxide being one example of a suitable base.
The buffer in the composition can be specifically carbonate, aspartate, glutamate, citrate, isocitrate, maleate, or succinate. These buffers help maintain the desired pH and stability of the pharmaceutical composition.
In addition to the above claims, the patent also describes an alternative composition that includes sodium thiosulfate at a concentration between about 0.3 M and about 0.6 M. This composition also includes a buffer at a concentration between about 0.01 M and about 0.05 M. However, the buffer options for this alternative composition are different and include sulfate, formate, acetate, propionate, butanoate, lactate, pyruvate, aconitate, a-ketoglutarate, fumarate, malate, and oxaloacetate.
The patent provides specific examples of buffers for this alternative composition, such as sulfate, formate, acetate, propionate, butanoate, lactate, pyruvate, aconitate, a-ketoglutarate, fumarate, malate, and oxaloacetate.
Overall, this patent describes pharmaceutical compositions that include sodium thiosulfate and a buffer, with specific concentrations and buffer options. These compositions have potential applications in the medical field and may offer benefits in terms of stability and pH control.
To know more about GlobalData’s detailed insights on Fennec Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
